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Abstract: Inherent biological viability and diversity of natural products make them a potentially rich 
source for new therapeutics. However, identification of bioactive compounds with desired 
therapeutic effects and identification of their protein targets is a laborious, expensive process. 
Extracts from organism samples may show desired activity in phenotypic assays but specific 
bioactive compounds must be isolated through further separation methods and protein targets must 
be identified by more specific phenotypic and in vitro experimental assays. Still, questions remain as 
to whether all relevant protein targets for a compound have been identified. The desire is to 
understand breadth of purposing for the compound to maximize its use and intellectual property, and 
to avoid further development of compounds with insurmountable adverse effects. Previously we 
developed a Virtual Target Screening system that computationally screens one or more compounds 
against a collection of virtual protein structures. By scoring each compound-protein interaction, we 
can compare against averaged scores of synthetic drug-like compounds to determine if a particular 
protein would be a potential target of a compound of interest. Here we provide examples of natural 
products screened through our system as we assess advantages and shortcomings of our current 
system in regards to natural product drug discovery. 
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Abbreviation list: 
ADME = absorption, distribution, metabolism, excretion;   
CDDI = Center for Drug Discovery and Innovation;   
HTS = High-throughput screening; 
MMOA = Molecular mechanism of action;   
MOI = Molecule of interest; 
NCI = National Cancer Institute;   
NME = New molecular entity;   
VS = Virtual screening;   
VTS = Virtual Target Screening. 
 
1.  Introduction 
Natural products are receiving renewed interest as potential sources for therapeutic agents since 
the number of new drugs discovered has dropped in recent years in spite of the growth in available 
synthetic compound libraries for drug discovery campaigns. Advanced drug discovery techniques 
developed in recent years to support high-throughput screening (HTS) that primarily used synthetic 
compounds can benefit new drug discovery efforts that focus on natural products. We are particularly 
interested in applying new computational methods we are developing towards drug discovery in 
natural products. 
At the University of South Florida (USF) in Tampa, there are numerous drug discovery projects 
underway, targeting primarily cancers and infectious diseases. The Center for Drug Discovery and 
Innovation (CDDI) provides shared resources to USF researchers [1]. Among these resources the 
CDDI provides natural product libraries of extracts, sub-fractions and individual compounds for 
screening in drug discovery campaigns. The CDDI is continually adding to and replenishing its 
collection of natural products, including marine natural products (extracts, sub-fractions and 
compounds) from new sources retrieved in annual expeditions in Antarctic waters [2]. As compounds 
are identified from these sources, we want to quickly identify potential targets for the compounds. 
This includes primary therapeutic targets but also potential alternate targets for repurposing, or 
unintended targets with potential detrimental interactions that could lead to adverse reactions.   
Previously we developed a Virtual Target Screening (VTS) system at H. Lee Moffitt Cancer 
Center & Research Institute on the USF campus. VTS can assess a molecule of interest (MOI) for 
potential interactions with other proteins by screening the MOI against a large collection of virtual 
protein structures [3]. VTS was originally developed towards cancer-related drug discovery and 
contains primarily human proteins. Also, VTS was developed, calibrated and used primarily with 
synthetic small molecules. Our current VTS system has been of use in cancer-related drug discovery 
projects in which VTS has brought to the attention of investigators potential off-target interactions of 
their lead MOIs. Here we describe testing of natural product libraries from the NCI and CDDI 
through VTS to assess benefits and shortcomings of our current VTS system with regards to natural 
products and with regards to drug discovery targeting infectious diseases (i.e. including more viral 
and bacterial proteins). The aim of this exercise is to improve and expand our VTS system to make it 
an effective tool with both natural products and synthetic compounds in drug discovery efforts for all 
disease types. 83 
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2.  Natural products versus synthetic compounds in drug discovery 
Humankind has always explored natural products to meet needs such as medicines, health 
supplements, dyes, inks, perfumes, pest repellents and many other uses. In regards to medicines, this 
exploration and utilization has been rewarding but, in many cases, the specific active compound, its 
unique characteristics (ex. chirality) and/or synthetic approaches were not known and, therefore, 
lacked optimization for the most effective sourcing, purification, formulation and dosing. Rational 
design of analogs to improve a compound was often not possible. The modern advances in synthetic 
chemistry and analysis allowed for more control in compound identification, design and 
development and, using high throughput synthesis and combinatorial chemistry, the number of 
available synthetic compounds for drug discovery has grown rapidly. For example, the ZINC 
database currently has virtual structures for over 35 million commercially available compounds 
ready for virtual screening and purchase of samples for experimental validation of virtual “hits” [4]. 
A “hit” is a compound that shows the desired effect based on computational scoring of its 
interactions with the virtual protein target, but the “hit” still needs experimental confirmation of the 
effect. The abundance of synthetic compounds has facilitated development of virtual and 
experimental high-throughput screening (HTS) in drug discovery; however, the yield of new drugs, 
based on new molecular entities (NMEs) discovered among synthetic compounds, has declined. 
Though the synthetic compounds should provide a diverse sampling of chemical space, synthetic 
collections lack relevant biodiversity and bioactivity due to such problems as having insufficient 
chiral representation, or lacking the size and complexity of the bioactive natural products with which 
they must compete in vivo. Some of this results from a lack of proper synthetic approaches and 
understanding to recreate a diverse representation of bioactive motifs, such as difficulties in covalent 
incorporation of bromide or chloride into organic compounds [5]. Synthetic compounds have been 
developed for the most part from conceptions and abilities of researchers to meet perceived 
biological needs whereas natural products have arisen under direct influence of highly demanding 
bioenvironmental pressures giving natural products, in general, an edge in filling new uses in real 
biological functions, i.e. biological validation.   
Another potential difficulty with synthetic compound “hits” is that they are often selected based 
on target-specific screening but fail to advance due to poor phenotypic effects in more complex 
experimental assays (e.g. cell-based assays) in which there can be unanticipated targets with different 
molecular mechanisms of action (MMOA) for the compound. A synthetic compound may have poor 
ADME (absorption, distribution, metabolism, excretion) characteristics that are not appreciated until 
later in drug development. Promising natural product compounds are typically found through a 
phenotypic approach in which sample extracts are tested in phenotypic assays and then the specific 
compounds in their bioactive state in the extract are determined through further separation and 
analysis (e.g. NMR or LC-MS). Dereplication is also performed to ascertain if it is, in fact, a new 
unexplored compound. Phenotypic screening, as typically used with natural products, has proven to 
be more productive than the target-based screening predominantly done with synthetic compound 
libraries. A recent review of new drugs between 1999 and 2008 found that there were 259 agents 
(183 small-molecule drugs, 20 imaging agents, and 56 therapeutic biologics) approved by the FDA, 
of which 75 were first-in-class drugs and 50 of these are small molecules [6]. Based on the authors’ 
analysis of published information accompanying the small molecule drugs, 28 were found through 
phenotypic screening, 17 were found through target-specific screening and there was insufficient 84 
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information for the other 5. The authors concluded that, phenotypic screening had been more 
successful in finding NMEs even though target-based screening had been used much more often in 
drug discovery during that period. Due to their biological origin and validation, natural product 
libraries should typically be enriched with phenotypically active compounds relative to most 
synthetic compound libraries. 
Lower than expected yield of new drugs from target-based approaches and synthetic compound 
libraries has brought natural products back into fashion for drug discovery campaigns [7‒13]. There 
have been improvements in applicable techniques, such as miniaturized high-throughput phenotypic 
assays to rapidly assess extracts and compounds [6]. Advances in extraction automation and 
fractionation techniques allow improvements in speed and quantity for testing extracts and 
compounds at sufficiently high concentrations to better determine phenotypic effect [14]. Individual 
compound structures can now be determined from only a few micro-grams of a compound obtained 
by analytical HPLC purification of samples and run through “nanoscale structure elucidation” using 
highly sensitive mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy [15]. 
The elucidated structures can then be screened rapidly against chemoinformatics databases in a 
dereplication step to determine uniqueness of a compound.   
Natural product collections can have overall advantages in bioavailability, biodiversity, 
biological validation and enrichment towards phenotypic activities. Natural products address 
biologically relevant chemical space whereas synthetic compound libraries are not as well focused 
on biological relevance. In addition, due to the variety of biosynthetic pathways, some of which are 
yet to be discovered, working with natural product materials, such as extracts, could lead to 
discovery of enzymatic activities that yield some of the more complex natural products that synthetic 
chemists cannot yet replicate. These discoveries can be elucidated to identify genes and proteins 
responsible for the activities, and then they can be exploited to ramp up production of natural 
products that were previously difficult to obtain, thereby improving on sourcing problems. These 
new discoveries can also be used in rational design starting with natural products or synthetic 
compounds to create compounds not seen previously (i.e., NMEs) [16,17]. 
3. Virtual  screening 
Virtual screening (VS) has proven to be a useful, cost-saving computational means of rapidly 
identifying compounds that have potential desired interactions, such as inhibition, with a protein 
target of interest. In typical VS, virtual compound structures from a library are individually docked 
and scored in a binding site of a virtual protein structure, such as the active site of an enzyme or an 
allosteric site. The compounds are then ranked by their scores and the top of the ordered list is 
considered to be enriched in compounds with potential for the desired interactions. Of course there 
are many caveats to successful VS, such as: having a properly prepared virtual protein structure; 
having docking/scoring algorithms that can rapidly and accurately generate and interpret docked 
poses of the compound with the protein; and having a means of experimentally validating the virtual 
“hits” to confirm that they do, in fact, show interaction with the protein of interest. Another caveat is 
to use libraries of compounds that have drug-like characteristics (ex. low molecular weight; 
solubility; potential for some ionic and/or hydrogen bonding). “Lipinski’s rule of 5” (a.k.a. “ro5”, 
500 Daltons or smaller; cLogP or calculated log P of 5 or less for solubility; 5 or less potential 
hydrogen bonds) is often used to describe these characteristics and is applied with some leniency in 85 
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building virtual compound libraries [18]. The concept of drug-likeness and its application in drug 
discovery has been evolving, as discussed in a recent review [19]. Since some of the most successful 
drugs currently on the market do not strictly comply with ro5, improvements have been developed 
for assessment of a compound, such as a quantitative estimate of drug-likeness (QED) approach 
which can assess a compound’s potential even if it does not strictly meet one or two of the ro5 
guidelines, but balances deviations in any one category against the compound’s overall distribution 
of properties [20]. 
There are many published successes with VS in which lead compounds were first identified by 
VS runs followed by experimental confirmation and then proceeded further into development 
towards becoming drug candidates, as described in a recent review [21]. One example is discovery of 
an inhibitor selective for CK2 kinase using a homology model of human CK2a and screening over 
400,000 virtual compounds from libraries at Novartis Pharma [22]. The CK2 kinase inhibitor found 
by Vangrevelinghe et al., (5-oxo-5,6-dihydroindolo[1,2-a]quinazolin-7-yl) acetic acid, was 
discovered using the DOCK 4.0 virtual screening application [23]. The inhibitor was very potent 
with an IC50 of 80 nM. As an example of our work with VS, we used Schrodinger’s Glide 2.7 
(Grid-based Ligand Docking with Energetics) [24] to virtually screen the NCI Diversity Set I, which 
contains 1,990 compounds [25], against S-adenosylmethionine decarboxylase (AdoMetDC), a key 
enzyme in polyamine synthesis and an important target in cancers [26]. The NCI Diversity Sets 
(currently NCI Diversity Set IV) are often used in initial screens in oncological drug discovery 
campaigns to test new targets since powder samples are available for free along with published data 
for each compound from the NCI for experimental confirmation. For the virtual protein structure, we 
used a crystal structure of human AdoMetDC solved at 2.24 Å resolution by Tolbert et al. available 
from the Protein Data Bank as entry PDBID 1I7M [27,28]. In our VS against AdoMetDC we 
identified one compound, NSC 354961, a 9-amino-acridine compound, which ranked #14 among the 
NCI Diversity Set compounds but NSC 354961 had the best experimental confirmation with an IC50 
of 12 μM. It served as a starting structure for further development. 
VS can be used in natural product drug discovery but it runs into problems when investigators 
are trying to find disruptors of protein-protein interactions because the binding areas are broader, 
protein dynamics on a larger scale become more important and larger more complex compounds are 
deemed necessary similar to the multiple amino acid residues from one protein that interact with the 
protein partner. Natural products collections can contain larger molecules but larger molecules can 
entail more rotatable bonds leading to more difficulty in sampling the range of poses. Gerwick and 
Moore, in their recent review of natural product drug discovery, call for further development and 
application of chemoinformatics and in silico screening (i.e. VS) to drug discovery with natural 
products [5]. They believe it presents exciting possibilities for the field. 
4.  Virtual target screening 
Virtual Target Screening (VTS) uses the NCI Diversity Set I as a reference for scoring 
MOI-protein interactions. Whereas VS docks multiple compounds against a single protein target to 
identify compound “hits”, the basic function of VTS is to dock a single MOI against multiple 
proteins to identify protein “hits”. A protein “hit” in VTS is a protein that has potentially important 
interactions with the MOI. VTS can bring to attention those proteins that may interact with the MOI 
so that further research may determine its selectivity. VTS can potentially identify adverse 86 
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interactions, allosteric interactions and possible targets for repurposing. VTS can also be used to test 
a focused library built around an MOI so that analogs of the MOI can be compared for their 
improvements in avoiding detrimental interactions and perhaps being more specific towards the 
intended targets of the original MOI. 
Although systems such as this are in their infancy, they can greatly reduce the time and expense 
of experimental analysis, allowing drug discovery efforts to focus on the most promising compounds 
and avoid compounds that may be too promiscuous or have adverse interactions that cannot be 
removed readily by further rational design work. 
We have published our work on VTS previously, discussing its development and validation 
against kinase targets [3]. Other groups have developed systems to screen individual compounds 
across protein collections and those have been discussed in recent reviews [29‒32]. These systems 
have a variety of names, such as reverse pharmacognosy, target fishing, inverse docking, virtual 
counter screening and drug repositioning and they have differing approaches to determining potential 
MOI-protein interactions, such as comparing the MOI to a known inhibitor of a protein or comparing 
the MOI to spatial requirements of a protein’s active site. Difficulties arise when there is no known 
inhibitor for comparison or the only known inhibitor is particularly weak or is a covalent inhibitor. 
Spatial definitions (i.e. “shapes”) of binding sites can have deficiencies if they are based on a static 
protein and limited to a few known small molecule interactions. 
In our VTS system, we used a calibration step for each protein to define standards an MOI 
should meet in order for that MOI-protein to be interpreted as a VTS “hit”. The NCI Diversity Set I 
is docked against the protein and statistics for each protein structure is calculated from the Glide 
Scores (GScores). The averages for the top 20, top 200 and top 50% of NCI compound docking 
scores are used as benchmarks. Since the NCI Diversity Set I has almost 2,000 compounds, we 
consider these averages to approximate the top 0.5%, 5%, and 25% marks, respectively. The use of 
these averages reduces the impact of skewing since extremely strong interactions by one or a few 
NCI compounds with a protein might set the bar too high for an MOI to register an impact as a true 
inhibitor even though the MOI may have relevant interactions with the protein that should be noted 
for their potential as adverse interactions. 
Adapting VTS for routine use in the CDDI with natural products and assuring sufficient 
coverage of protein targets relevant in infectious diseases requires critical analysis of current 
shortcomings as well as demonstration to new users of the potential of VTS in infectious disease 
drug discovery. This is also an opportunity to assess the needs for improvement in VTS’s overall 
performance, capacity and quality. The purpose of this exercise in screening NCI and CDDI natural 
products is to demonstrate the usefulness of VTS in identifying potential off-target interactions with 
human proteins and to determine those issues that must be addressed in our current VTS system to 
optimize it for natural product drug discovery. 
5.  Materials and methods 
5.1. Virtual compound libraries 
The NCI Diversity Set I, consisting of 1,990 virtual compounds, was obtained from the National 
Cancer Institute’s (NCI) Developmental Therapeutics Program (DTP) and used as described 
previously for our VTS system [3,25]. 87 
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The NCI natural Product Set II includes 120 compounds [33].  Due to cost and time 
considerations, we selected 67 compounds that ranged from 314 to 692 Daltons in a loose application 
of “Lipinski’s rule of 5”. These compounds were screened in VTS. The NCI DTP website also 
provides links to published experimental data on the compounds in their virtual libraries [34]. This 
allows for comparison and validation of VTS “hits” against known experimentally-determined 
interactions of the compounds when the data is available.   
The CDDI library provided to us contained virtual structures for 160 natural product 
compounds, many originating from marine sources [1]. These are from the larger collections at the 
CDDI, which include over 2,500 extracts and 950 characterized bioactive compounds. Again, due to 
cost and time consideration, we selected 87 of these compounds for VTS testing with a range of 
350–675 Daltons. 
5.2. Ligand preparation 
Prior to screening all compounds were prepared using the LigPrep utility in Schrodinger's 
Maestro software [35,36]. LigPrep generates 3D structures of all tautomers, ionic states and 
stereoisomers of input compounds. In the case of NCI compounds the structure files have indicated 
chiralities of some stereo centers. Therefore, when preparing the ligands, only the unspecified centers 
were allowed to sample different chiralities. For CDDI compounds however, to reduce computational 
time and the amount of isomers, all the chiralities were inferred from the 3D structure. As a result, 
LigPrep generated a total of 1133 structures from the 67 original NCI compounds and, because no 
chiralities were varied in the case of CDDI set, a total of only 103 structures resulted from LigPrep 
for the 87 original CDDI compounds. 
5.3. Virtual target screening 
Our VTS system was developed in a Linux environment and consists of a script (written in Perl) 
that repeatedly executes Glide via a command line call. Input files include: 1) the prepared protein 
structures (prepared using Schrödinger’s Protein Preparation Wizard application [35]); 2) the list of 
average scores for the proteins determined when they were calibrated by docking the NCI diversity 
set; and 3) the file containing one or more MOIs. A typical VTS run is described above and in our 
previous publication [3]. We have developed a user-friendly interface using CHARMMing [37] to 
invoke VTS windows that allow: 1) uploading or drawing of MOI structures; 2) selection of proteins, 
either all proteins or subsets selected by criteria, such as species and/or protein type (ex. kinases); 3) 
initiate and monitor a job with ongoing updates of estimated finish time; and 4) review the output. 
Currently, the CHARMMing based VTS is only available internally at the University of South 
Florida and H. Lee Moffitt Cancer Center. Future development of VTS will include a URL available 
for a broader user group. The VTS protein collection currently is 1,418 structures represented by 
1,567 grids (some having multiple sites) for prepared and calibrated proteins. Predominantly it is 
human proteins (~71%) since VTS was developed initially towards oncological drug discovery 
projects but the collection also contains some bacterial (~11%), viral (~5%) and fungal (~1%) 
proteins as well as murine, bovine and other species. The proteins were originally selected from the 
Protein Data Bank and primarily wild-type entries were selected [28]. 
We selected primarily human proteins as the targets for this VTS exercise, which yielded 1,059 88 
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target grids representing 1,011 unique crystal structures. For this exercise with a large number of 
MOIs to process in VTS, we estimated there would be over one million docking and scoring 
calculations. Therefore, the compounds were divided into 25 separate files, each containing subsets 
of 30–60 structures. This was done to effectively parallelize the VTS calculations. Each of these 
subsets was then uploaded through the VTS web interface’s MOI upload section. A screening job 
was then launched from the VTS web interface for each of the 25 subsets to be screened against all 
1,059 target grids. On average each job took approximately 30 hours to complete. When analyzing 
the results of the screening jobs, a compound-protein was deemed to be a “hit” if the score 
outperformed the average score for the top 20 NCI diversity set compounds for that protein structure. 
The “hits” were compared against the literature for consistency with published experimental data. 
The PubChem database was used to look-up experimental activities for the compounds that hit one 
or more targets [38,39]. 
5.4. Hardware 
VTS was originally developed and run on a Dell Precision 490 workstation running Fedora 8 
Linux with dual Xeon 3.06 GHz processors, 4 GB RAM and a 250 GB hard drive. This was 
sufficient when running one or a few MOIs but, for the larger sets of MOIs for the 67 NCI natural 
products and the 87 CDDI natural products, we incorporated execution on a local cluster we have 
developed in the Virtual Screening & Molecular Modeling Core at H. Lee Moffitt Cancer Center & 
Research Institute. This cluster is comprised of 6 racks each containing 8 Intel-based dual core 
desktop computers connected via a NETGEAR Pro Sage 16 router (model GS716T). 
5.5. Graphics & modeling 
Visualization of docked MOIs in protein targets was performed with Schrödinger’s Maestro, a 
graphical user interface that allows modeling and facilitates use of many of Schrödinger’s 
applications with the models, such as MacroModel and Glide [24,35,40]. Refined depictions used for 
publication figures were developed using Schrödinger’s PyMol [41]. 
6. Results 
6.1. VTS on NCI natural products 
Upon compilation of the results of all the jobs, a total of 13,278 hits were identified for the NCI 
Natural Products Set II compounds tested. For 4 of the screened NCI molecules VTS identified a total 
of 16 targets against which screened compounds were found active in one or more experimental assays 
(Table 1). The most “active” MOI Daunorubicin (Figure 1) hit a total of 6 unique proteins. The most 
interesting of those hits can be considered the Lck tyrosine kinase protein. Daunorubicin has hit 5 
different structures that represent this protein. Moreover in at least two reported assays Daunorubicin 
had indeed shown activity against this particular target. It may be speculated that a compound hitting 
multiple structures of the same protein may indicate likely activity against that protein. In addition, 
results of the NCI natural products screen show preference of some compounds towards one or more 89 
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Table 1. Top NCI natural products screen hits. Compounds with known activity 
against the targets that have been identified as hits in the VTS screen. Column 1 
contains the NSC number of the compound, column 2 contains the common name of 
the compound, column 3 contains 2D sketch of the compound, column 4 contains 
the name of the protein targeted by the compound, column 5 shows the number of 
unique structures representing the target identified as a hit for the given MOI, 
column 6 is the number of assays that have reported activity of the MOI against this 
target. 
NSC Compound 
Name 
Structure  Target  # of unique 
structures 
identified 
by VTS 
# of assays 
reporting 
activity 
82151  Daunorubicin 
  
Lck tyrosine kinase 
 
Estrogen Receptor Alpha 
 
Epidermal  Growth  Factor 
Receptor 
 
Thyroid hormone receptor 
 
Mitogen  Activated  Protein 
Kinase 14 
 
Fyn tyrosine kinase 
5 
 
2 
 
3 
 
 
1 
 
1 
 
 
1 
2  
 
8  
 
1  
 
 
4  
 
1  
 
 
1  
5159  Chartreusin 
  
Urokinase‐type  plasminogen 
activator* 
 
Heat  Shock  Protein  HSP 
90‐alpha** 
 
Cyclin‐Dependent Kinase 5 
2 
 
 
1 
 
 
1 
1  
 
 
1  
 
 
1  
221019 
 
Wortmannin 
  
Cyclin‐Dependent Kinase 2 
 
Serine/threonine kinase 
PIM1 
 
Src tyrosine kinase 
 
Lck tyrosine kinase 
 
6 
 
 
2 
 
 
2 
 
1 
1  
 
 
1  
 
 
1  
 
2  90 
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* - VTS screening included and hit the human version of the protein while the experimental data is 
on mouse. 
** - VTS screening included and hit the human version of the protein while the experimental data is 
on a structurally similar Plasmodium falciparum. 
 
Figure 1. Daunorubicin docked into Lck. Daunorubicin’s docked pose according to 
the VTS docking procedure. Inset shows the local hydrogen bond interactions in 
yellow dashed lines as well as the residues with which these interactions are formed 
in stick representation. The Lck structure was 1QPJ.pdb [52]. 
Cyclin‐Dependent Kinase 5 
 
3‐phosphoinositide‐depen
dent protein kinase 1 
 
 
1 
 
 
1 
 
1  
 
 
1  
345647  Chaetochromin 
  
Glutathione-S-transferase 
Omega 1 
 
 
1 
 
 
 
 
 
2  91 
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protein families as can be seen in the case of Wortmannin and a kinase family (Table 1). It should be 
noted however that kinases are disproportionally well represented (25%) in our protein database due 
to their importance in cancer. Still an insight like this can be used to gauge the potential for more 
specific targeting as well as possible promiscuity of an MOI. 
6.2. VTS on CDDI natural products 
The screening of CDDI compounds against our database has also yielded interesting results. 
Although assay information is not as readily available for these compounds, the results of the VTS 
can still show interesting trends and insights valuable for drug discovery. Table 2 shows the top 40 
hits where the MOI has outperformed the top performers of the calibration set by the largest margin,   
Table 2. Top CDDI set hits. Top 40 hits based on the largest margin by which an 
MOI outperformed the top 20 calibration set average. First column contains the 
name of the target protein with co-crystallized ligand identifier in square brackets. 
Second column indicates the percentage by which a given MOI outscored the 
average docking score of the top 20 calibration set molecules for that target. Third 
column contains the rounded molecular weight of a docked MOI and serves as its 
identifier. The table is sorted by the molecular weight. 
Target 
Outperformed 
calibration by (%) 
Molecular Weight 
(compound ID) 
[R11]Coagulation factor x  28  287 
[L1G]HCK 28  368 
[NHB]Histone deacetylase 8  30  372 
[NHB]Histone deacetylase 8  24  372 
[NHB]Histone deacetylase 8  36  374 
[AO5]Methionine aminopeptidase 2  35  374 
[GIP]Protein (lactoylglutathione lyase)  35  374 
[NHB]Histone deacetylase 8  29  374 
[GIP]Protein (lactoylglutathione lyase)  30  374 
[AO2]Methionine aminopeptidase 2  23  374 
[NHB]Histone deacetylase 8  26  437 
[NHB]Histone deacetylase 8  23  530 
[HYF]Orphan nuclear receptor pxr  35  587 
[HYF]Orphan nuclear receptor pxr  33  587 
[QPP]CAMK1D 32  587 
[SWF]CYP2C9 26  587 
[DEO]Macrophage metalloelastase  20  587 
[XLD]Coagulation factor x heavy chain  30  587 
[RAP]Fkbp25 36  587 
[SDK]Cathepsin K  30  587 
[POS]Cathepsin K  30  587 
[INA]Cathepsin K  29  587 
[POS]Cathepsin K  28  587 92 
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[BOG]p38-alpha(MAPK14) 25  587 
[2CA]Cathepsin k  27  587 
[FMM]Epidermal growth factor receptor  23  625 
[L1G]HCK 39  629 
[471]Peroxisome proliferator activated receptor  42  629 
[U66]Protein farnesyltransferase alpha subunit  31  629 
[CIU]Epoxide hydrolase 2- cytoplasmic  29  629 
[POS]Cathepsin K  33  629 
[SDK]Cathepsin K  31  629 
[HYF]Orphan nuclear receptor pxr  25  629 
[155]Urokinase-type plasminogen activator  27  629 
[SAH]Histamine MeXferase (Ile105Var)  22  629 
[AIJ]Estrogen receptor  21  629 
[BNE]Protein farnesyltransferase alpha subunit  21  629 
[BOG]p38-alpha(MAPK14) 23  629 
[LA1]Integrin alpha-L  31  663 
[LA1]Integrin alpha-L  19  674 
 
Figure 2. 368 docked into HCK. 368’s docked pose according to the VTS docking 
procedure. Inset shows the local hydrogen bond interactions in yellow dashed lines 
as well as the residues with which these interactions are formed in stick 
representation. The HCK structure was 2COI.pdb [53]. 93 
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thus making these compounds more likely to be tighter binders to the indicated targets. It can be seen 
that there are a number of molecules, as identified by their unique molecular weight that hit several 
targets, as is especially the case with compounds 374, 587 and 629. Once again, this may be an early 
indicator of potentially promiscuous compounds. At the other end of the spectrum are compounds 
such as 287, 368 (Figure 2), 437, 530 and 674. These compounds only hit one target. Especially 
interesting are those compounds with lower molecular weight as it is easier for a larger compound to 
score high based on the increased number of favorable interactions it can form with the protein. If a 
smaller sized yet still a drug-like compound such as 368 significantly outperforms a calibration set 
for a single particular target, it may be worthy of a further inquiry as a potential binder to that protein 
7. Discussion 
We have used 67 compounds from the NCI Natural Products Set II to test our VTS system for 
its ability to virtually identify potential protein targets, i.e. “hits” that can be compared to published 
data for those compounds. We have also used 87 compounds from the CDDI natural products to 
assess their potential interactions with protein targets when they were screened through VTS. The 
work has also brought to light improvements that can be made to the current VTS system to make it 
more applicable to our new areas of application in drug discovery and development: infectious 
diseases and natural products, particularly marine natural products. There is an unmet need for 
large-scale drug discovery efforts with marine natural products [42,43]. There is also opportunity for 
these large-scale efforts with marine natural products and natural products in general to be used more 
in academic settings, such as the CDDI [44]. Drug discovery efforts with marine natural products 
have been successful with 13 products in clinical trials in 2010 and so these efforts should be 
expanded to take advantage of new natural products from new marine sources [45]. In order to 
scale-up these efforts and make them more productive, particularly as natural product libraries grow, 
innovation is needed [46]. We believe that VTS is an innovative, cost-effective approach to address 
the needs for rapid identification and appraisal of natural products. Besides our previous paper [3] in 
which we compared our VTS results against experimental data focusing on kinases, there are other 
recent reports in which other groups have compared results from computational drug repurposing 
applications against experimental data demonstrating the usefulness of the tools [47,48]. 
This exercise demonstrates that VTS can identify potential promiscuity of natural product 
compounds that may deter further development of an MOI if the promiscuity is experimentally 
confirmed for some of the “hit” proteins. VTS can also give ideas of other targets that may not have 
been considered previously for the MOI. However, since our VTS protein collection is limited, we 
cannot yet consider the VTS runs as comprehensive searches. There may be more proteins that 
would arise as “hits” for these compounds if those proteins had been included. Other systems are 
now available online for screening compounds against collections of protein structures, such as 
HitPick [49], ChemMapper [50], and Mantra [51]. A comparison of VTS and other target finding 
applications was beyond the scope of this study since our purpose was to analyze VTS with regards 
to natural products and infectious disease targets. However, we did test two of the top scoring 
compounds (wortmannin and daunorubicin) from the NCI Natural Products II and got similar hits of 
kinase proteins as were found by HitPick. A thorough study comparing the various target finding 
applications is certainly warranted now that more applications are published but it should be 
comprehensive with regards to ligands (small synthetic molecules and natural products). We believe 94 
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the VTS approach has benefits in that it can be used towards different sites on a protein, such as 
allosteric sites, for which there may not be any previously known ligands. We can use Schrödinger’s 
SiteMap as a means of identifying potential binding sites [54,55]. The drug-like molecules of the 
NCI Diversity set can quickly calibrate new sites even when there is no previous data. Many other 
applications are dependent on previously known ligands for specific binding sites in order to make 
their assessment of an MOI’s interactions.   
VTS also can be used to compare an MOI against known inhibitors of VTS “hit” proteins and to 
compare the MOI against its own analogs to test focusing by functional groups as rational design is 
applied to the MOI to generate improved analogs. Some of the analogs may show more specificity to 
the intended target and generate fewer VTS “hits”, suggesting that the analog is an improvement 
over the original MOI. With regards to a known inhibitor, if the MOI shows more specificity (fewer 
VTS “hits”) than the inhibitor, this can increase interest for the MOI. 
The main purpose of VTS is to identify new targets for an MOI, whether they are new targets 
for repurposing or targets that may indicate possible adverse interactions. For VTS to be effective 
towards this purpose, we need to increase our collection of proteins. Since VTS was originally 
developed for supporting oncological drug discovery projects, the emphasis was for inclusion of 
primarily human proteins. For testing compounds in VTS for infectious disease projects, we need a 
great increase in protein structures from viruses, bacteria and other microorganism that are relevant 
to those diseases. We need to grow the VTS protein collection as much as possible using as many 
structures from the Protein Data Bank, but we still want to focus on those structures that have high 
resolution (~2.0 Å or less) and primarily wild-type proteins. We realize now that, even towards 
oncological drug discovery, proteins from microorganisms are important in VTS since often the 
beneficial microbes in the patient’s gut microbiota can be adversely affected by drug therapy. And of 
course there need to be more proteins represented for the problematic microorganisms in infectious 
diseases. 
We intend also to include more proteins involved in protein-protein interactions. The target sites 
may be more difficult to isolate for Glide grids and so multiple copies of the protein structure with 
grids at different sites could be used. We can use Schrödinger’s SiteMap utility to identify potential 
binding sites as part of the protein preparation and center the Glide grids on those sites [54]. 
Disruptors of protein-protein interactions can conceivably be larger than typical small molecule 
substrates of enzyme active sites and so we would want to expand VTS to deal with larger MOIs. 
This would require an additional approach to calibrating the prepared proteins. We can envision 
using a designed virtual di-, tri- or tetra-peptide or peptidomimetic library for an additional set of 
averages to use in calibration and VTS analysis. These averages of larger molecules would be of use 
for larger MOIs, which can occur with natural products. Another possible improvement is to 
incorporate into VTS an assessment of ligand binding efficiencies. We can improve overall 
interpretation of VTS dockings by taking into account the number of non-hydrogen atoms to avoid 
inflation of the scores for larger ligands. The basic approach would be to divide the GScore by the 
number of non-hydrogen atoms. In addition, approaches being developed to assess drug-likeness 
need to be incorporated, such as the QED approach [20]. Another issue to address in improving VTS 
is the quality of the prepared proteins. MacroModel has been used in VS and VTS for achieving a 
relaxed state, more in vivo-like, for the protein compared to the original crystal structure. However, 
we might think of this as local relaxation of protein domains, whereas a thorough molecular 
dynamics (MD) relaxation of the protein, in which it is put in a virtual environment that simulates the 95 
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individual water molecules and ions, can relax the protein to a global energy minimum in solution 
that may be even more pertinent to creating the protein in a realistic state for screening. In the last 
few years MD applications, such as Schrödinger’s Desmond, have become available so that we can 
now implement MD into our protein preparation steps [56]. This implies that we should reprocess 
our existing protein collection with MD as well as apply MD to new proteins. MD requires more 
powerfully processing power and memory, which we can now access with clusters making these 
improvements feasible. 
VTS and VS are developed primarily towards screening for non-covalent interactions of ligands 
and proteins. High-throughput virtual screening of potential covalent inhibitors has not been 
developed to our knowledge. This would be an interesting addition but does present many difficulties, 
even to develop a limited application. It would require a list of potential reactant groups, identifying 
key reactive residues in a protein that could be in play, and an algorithm to compare distances, 
charges and intermediates. It would seem to preclude the actions of cofactors and other agents. So 
covalent screening, at least with current tools, would be too challenging. However, it is interesting to 
contemplate such tools and their potential benefits in drug discovery. 
8. Conclusion 
This work has shown the potential for VTS with natural products to identify targets that may 
represent new purposes for the MOI, possible promiscuity of an MOI, or possible adverse 
interactions that warrant further investigation. Our VTS system can serve these purposes but we have 
used this current work to identify issues to improve in order to maximize the use and benefits of VTS 
for infectious disease drug discovery projects, particularly with newly acquired marine natural 
products. 
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